BACK (IMAC Holdings) Loans Receivable: $0.00 Mil (As of Sep. 2025)


What is IMAC Holdings Loans Receivable?

IMAC Holdings BACK Loans Receivable is $0.00 Mil as of Sep. 2025. The stock has 7 warning signs investors should review.

IMAC Holdings's Loans Receivable for the quarter that ended in Sep. 2025 was $0.00 Mil.

IMAC Holdings Loans Receivable Historical Data

* Premium members only.

The historical data trend for IMAC Holdings's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IMAC Holdings Loans Receivable Chart

IMAC Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Loans Receivable
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

IMAC Holdings Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

IMAC Holdings Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.

Frequently Asked Questions Learn more about Loans Receivable →
What does a Loans Receivable of $0.00 Mil mean?
IMAC Holdings (BACK) has a Loans Receivable of $0.00 Mil as of Sep. 2025. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on IMAC Holdings and its competitors.
Is IMAC Holdings' Loans Receivable too high?
IMAC Holdings' current Loans Receivable is $0.00 Mil.
How does IMAC Holdings' Loans Receivable compare to FCHS and NHLG?
IMAC Holdings' Loans Receivable of $0.00 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Loans Receivable for a Healthcare Providers & Services company?
A good Loans Receivable depends on the Healthcare Providers & Services industry context. However, Loans Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Loans Receivable mean?
A high Loans Receivable can signal that a stock is expensive relative to its fundamentals. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on IMAC Holdings and its competitors. IMAC Holdings's current Loans Receivable is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IMAC Holdings stock overvalued right now?
IMAC Holdings (BACK) has a current Loans Receivable of $0.00 Mil. The current Loans Receivable is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Loans Receivable calculated?
Loans Receivable is calculated from a company's financial statements. For IMAC Holdings (BACK), the current Loans Receivable is $0.00 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

IMAC Holdings Business Description

Address 3401 Mallory Lane, Suite 100, Franklin, TN, USA, 37067
IMAC Holdings Inc is engaged in providing services related to proteomic products that identify and support oncology clinical treatment decisions and biopharmaceutical drug development. The Company has determined that it currently operates in a single segment, precision medicine in cancer treatment, located in a single geographic location, the United States.